Acalabrutinib Real world Italian obSErvational study -ARISE - ARISE

Study identifier:D8221R00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Acalabrutinib Real world Italian obSErvational secondary data collection study of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia.

Medical condition

Chronic Lymphocytic Leukemia

Phase

Phase 4

Healthy volunteers

No

Study drug

acalabrutinib

Sex

All

Estimated Enrollment

190

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 08 Aug 2023
Estimated Primary Completion Date: 28 Feb 2030
Estimated Study Completion Date: 28 Feb 2030

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Dec 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Yghea

Inclusion and exclusion criteria